Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites.

Literature DB >> 21475423

Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites.

Achuthan Sourianarayanane, David S Barnes, Arthur J McCullough.

Abstract

Entities: Chemical Disease Species

Year: 2011 PMID： 21475423 PMCID： PMC3061020

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

18 in total

1. Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.

Authors: Georgios Kalambokis; Andreas Fotopoulos; Michael Economou; Epameinondas V Tsianos
Journal: Nephrol Dial Transplant Date: 2005-08-16 Impact factor: 5.992

2. Octreotide in the treatment of refractory ascites of cirrhosis.

Authors: Georgios Kalambokis; Andreas Fotopoulos; Michael Economou; Epameinondas V Tsianos
Journal: Scand J Gastroenterol Date: 2006-01 Impact factor: 2.423

3. Treatment of hepatic hydrothorax with vasoconstrictor drugs.

Authors: Georgios Kalambokis; Epameinondas V Tsianos
Journal: Scand J Gastroenterol Date: 2007-04 Impact factor: 2.423

4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Authors: P Angeli; R Volpin; G Gerunda; R Craighero; P Roner; R Merenda; P Amodio; A Sticca; L Caregaro; A Maffei-Faccioli; A Gatta
Journal: Hepatology Date: 1999-06 Impact factor: 17.425

5. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.

Authors: D N Cruz; R L Mahnensmith; H M Brickel; M A Perazella
Journal: Clin Nephrol Date: 1998-08 Impact factor: 0.975

6. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.

Authors: Puneeta Tandon; Ross T Tsuyuki; Lesley Mitchell; Michael Hoskinson; Mang M Ma; Winnie W Wong; Andrew L Mason; Klaus Gutfreund; Vincent G Bain
Journal: Liver Int Date: 2008-05-19 Impact factor: 5.828

7. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

Authors: C Alessandria; A Ottobrelli; W Debernardi-Venon; L Todros; M Torrani Cerenzia; S Martini; F Balzola; A Morgando; M Rizzetto; A Marzano
Journal: J Hepatol Date: 2007-05-24 Impact factor: 25.083

8. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.

Authors: Virendra Singh; Prashant C Dheerendra; Baljinder Singh; Chander K Nain; Divya Chawla; Navneet Sharma; Ashish Bhalla; Sushil K Mahi
Journal: Am J Gastroenterol Date: 2008-06 Impact factor: 10.864

Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites.

1. Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.

2. Octreotide in the treatment of refractory ascites of cirrhosis.

3. Treatment of hepatic hydrothorax with vasoconstrictor drugs.

4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

5. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.

6. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.

7. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

8. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.

9. Midodrine improves chronic hypotension in hemodialysis patients.

Review 10. Fluid retention in cirrhosis: pathophysiology and management.

1. What is the Role of Midodrine in Patients with Decompensated Cirrhosis?

2. Refractory ascites-the contemporary view on pathogenesis and therapy.